Mark Breidenbach
Stock Analyst at Oppenheimer
(1.71)
# 2,782
Out of 4,876 analysts
56
Total ratings
32.2%
Success rate
0.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $11.64 | +157.73% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.18 | +1,001.69% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.73 | +882.66% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $7.54 | +1,159.95% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $3.53 | +608.22% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.74 | +1,249.53% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $8.96 | +2,578.57% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $4.43 | +3,511.74% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.66 | +321.69% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.26 | +2,439.68% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $1.69 | +787.57% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.22 | +9,736.07% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.02 | +955,782.35% | 2 | May 12, 2020 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $11.64
Upside: +157.73%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.18
Upside: +1,001.69%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.73
Upside: +882.66%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $7.54
Upside: +1,159.95%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $3.53
Upside: +608.22%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.74
Upside: +1,249.53%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $8.96
Upside: +2,578.57%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $4.43
Upside: +3,511.74%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.66
Upside: +321.69%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.26
Upside: +2,439.68%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $1.69
Upside: +787.57%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.22
Upside: +9,736.07%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.02
Upside: +955,782.35%